CD8A and neoplasm: Variations on the same vaccine platform design, specifically relying on cathepsins for the enzymatic cleavage, were subsequently used to generate peptide-specific CD8+ T cells against influenza antigens [133], tumour antigens [134] and parasite antigens [135].